$HCM

HUTCHMED and AstraZeneca submitted a US NDA for ORPATHYS® (savolitinib) plus TAGRISSO® (osimertinib) to treat MET-driven EGFR-mutated lung cancer, supported by the SAFFRON Phase III trial showing improved PFS and OS. The application seeks approval for a biomarker-directed treatment option for patients who progressed on EGFR-TKI therapy. HUTCHMED's Johnny Cheng highlighted the significance of this filing for US patients, building on the drug's approval in China.

HUTCHMED and AstraZeneca submitted a US NDA for ORPATHYS plus TAGRISSO in MET-driven EGFR-mutated lung cancer. The Phase III SAFFRON trial showed significant improvements in progression-free and overall survival over chemotherapy. FDA approval is pending. (HCM, AZN)

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) has started a Phase Ia global clinical trial of HMPL-A830, an ATTC drug candidate, in patients with advanced solid tumors. The trial aims to assess the safety, tolerability, and preliminary efficacy of HMPL-A830. HUTCHMED also announced a licensing agreement with GSK for the development and commercialization of HMPL-A830 outside of Mainland China, Hong Kong, Macau, and Taiwan.

HUTCHMED (HCM) began a global Phase Ia trial of HMPL-A830, a cancer drug targeting KRAS and EGFR, in patients with advanced solid tumors. The first patient was dosed in China on September 24, 2026. The study aims to assess safety, tolerability, and dosage. GSK obtained rights outside Greater China under an agreement signed September 3, 2026.

HUTCHMED (HCM) and GSK (GSK) signed a global licensing deal for HMPL-A830, targeting colorectal, pancreatic, and lung cancers. HUTCHMED received a $110M upfront payment, with potential milestone payments up to $1.3B and tiered royalties. GSK gains worldwide rights outside Greater China, with HUTCHMED leading global Phase I trials starting in H2 2026.

HUTCHMED (China) (NASDAQ:HCM) reported H1 2026 results, with China product sales up 40% driven by Elunate and Sulanda. Ex-US FRUZAQLA sales rose 70%, maintaining full-year revenue guidance of $330M-$450M. R&D expenses increased to $79M, reflecting investments in clinical trials and AI. The company has a cash reserve of $1.4B and is advancing multiple clinical trials. Management highlighted growth opportunities in hematology and immunology fields.

Ionis (IONS) and Milestone (MIST) gained FDA approvals for neurology and cardiology drugs. Biogen (BIIB) and AstraZeneca (AZN) also received regulatory nods for Alzheimer's and cancer treatments. Novavax (NVAX) secured global approvals for its COVID-19 vaccine. TScan (TCRX) and Novartis (NVS) announced job cuts. Novartis (NVS) and HUTCHMED (HCM) struck deals worth up to $3.2B and $1.295B respectively.

ACT Energy, Cascadia Minerals, Condor Energies, Highcliff Metals, Hammond Manufacturing, NiobiumX, NSJ Gold, PrairieSky, Riverside, BioSyent, Surge Energy, Swiss Water, and Total Energy hit 52-week highs. ACT Energy and Swiss Water received TSX approval for share buybacks. Cascadia reported drill results. Condor achieved a production record. PrairieSky reported Q3 revenues of $10.9M and funds from operations of $133.1M. BioSyent, Surge, and Total declared dividends.

Summit Therapeutics (SMMT) shares rose 10.1% to $16.07 after positive Phase III study results. Snowflake (SNOW) gained 20.6% following better-than-expected earnings. HUTCHMED (HCM) rose 13% after a licensing deal. Tesla (TSLA) increased 5.7% to $377.53. Other stocks like Robinhood (HOOD), Coinbase (COIN), and others also saw gains.

Hutchmed (HCM) secured a licensing deal with GSK (GSK), receiving $110M upfront and up to $1.185B in milestones. Panmure and Cavendish reiterated 'buy' ratings, with target prices of 400p and 370p respectively, citing undervalued oncology pipeline and GSK's validation. Hutchmed's shares rose 15% to 205.84p.